New applications like Veeva LIMS Basics and PromoMats Basics drive speed and growth
/PRNewswire/ –Veeva Systems (NYSE: VEEV) today announced that more than a hundred biotech companies have chosen Veeva Basics to improve clinical, regulatory and quality operations. More and more biotech companies in the US and Europe are laying the foundation for their growth with a simple, industry-leading off-the-shelf solution that can adapt to evolving business needs.
With Veeva Basics, biotech companies benefit from best-in-class line-of-business applications that are pre-configured and pre-validated for rapid deployment. Built on the Vault platform, Veeva Basics enables biotechs to move to a comprehensive Vault solution without migration. This gives companies the technology and support for efficient processes in all important business areas – for the present and the future.
“More than a hundred biotech leaders from sixty companies gathered at the Veeva R&D and Quality Summit in Boston to learn, network and help shape the future of Veeva Basics. We are proud of our contribution to the success of emerging biotech companies and will continue to add innovative new applications that can be implemented quickly to support the development of new medicines,” said Steve Harper, general manager at Veeva Basics.
To meet critical quality control (QC) and commercial needs, Veeva Basics adds two new applications:
- Veeva LIMS Basics for virtual enterprises to enable CMO oversight, including batch release and certificate of analysis (CoA) capabilities. Stability functionality is planned for 2026.
- VeevaPromoMats Basics for complete content lifecycle management, including approval, storage and distribution of advertising content and claims management.
Veeva LIMS (Laboratory Information Management) Basics and PromoMats Basics are expected to be available in early 2026. Built on the proven Vault platform, Veeva Basics applications help customers scale their technology infrastructure to support their growth. Learn more about Veeva Basics at veevabasics.com.
This is what biotechs say about Veeva Basics:
“As a rapidly growing company, we have recognized the value of Veeva Basics to standardize our processes based on industry best practices. The ability to rely on a flexible solution that works while providing easy access to the Veeva Vault platform as we grow gives us the confidence to meet future needs,” commented Richard Tornai, Senior Director IT, R&D Clinical at Structure Therapeutics.
“Establishing a foundation for our quality and regulatory processes was a priority. We needed a compliant and cost-effective document and data management solution. We believe Veeva Basics meets these needs and more, offering logical workflows, a library of templates for SOPs and forms, and easy and effective training,” said Bryan Ball, Chief Technical Operations Officer at Whitehawk Therapeutics.
“Veeva Basics delivered a best-in-class solution with global support for upskilling our employees. Veeva’s commitment to delivering innovation to biotechs and focus on customer success make the company the ideal partner,” said Bernhard Irlinger, Head of Quality at AiCuris.
About Veeva Systems
Veeva provides the industry cloud for life sciences with software, data and business consulting. Veeva represents innovation, product excellence and customer success, serving more than 1,500 customers ranging from the world’s largest biopharmaceutical companies to emerging biotech companies. As a public benefit corporation, Veeva strives to align the interests of all stakeholders, including customers, employees, shareholders and the industries in which it operates. For more information, visit veeva.com/eu.
Veeva Forward-Looking Statements
This press release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from using our products and services. These statements are based on our current expectations. Actual results may differ materially from those expressed in this press release and we undertake no obligation to update such statements. There are numerous risks that could adversely affect our results of operations, including the risks and uncertainties disclosed in our Form 10-Q for the period ended July 31, 2025, which can be found here (see pages 33 and 34 for a summary of the risks that could affect our business), and in our subsequent SEC filings, which can be accessed at sec.gov.
Contact:
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
[emailprotected]
Logo: https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo_v2.jpg